Neuberger Berman Group
CMPX icon

Neuberger Berman Group’s Compass Therapeutics CMPX Stock Holding History

Neuberger Berman Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$43.3K Buy
19,792
+3,439
+21% +$10.2K ﹤0.01% 2296
2026
Q1 		$86.5K Buy
16,353
+3,546
+28% +$20.5K ﹤0.01% 2085
2025
Q4 		$68.8K Buy
+12,807
New +$59.1K ﹤0.01% 2037

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Neuberger Berman Group's CMPX Position: Q2 2026 in Review

Neuberger Berman Group increased its Compass Therapeutics (CMPX) stake by 21% in Q2 2026, buying an estimated $10.2K and bringing the position to 19,792 shares worth $43.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2296.

Neuberger Berman Group first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. The position peaked at $86.5K in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Neuberger Berman Group held 19,792 shares of Compass Therapeutics worth $43.3K as of Q2 2026.
  • Neuberger Berman Group bought 3,439 Compass Therapeutics shares in Q2 2026, an estimated $10.2K.
  • Compass Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2296 holding.
  • Neuberger Berman Group first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Neuberger Berman Group's Compass Therapeutics position peaked at $86.5K in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.